A case of vaccine-induced immune thrombotic thrombocytopenia (VITT) in a 43-year-old female patient

Iavorska, I. V.; Brzozowski, Kamil; Chudobiński, Cezary; Krzemińska, Emilia; Wypasek, Ewa; Treliński, Jacek

doi:10.20452/pamw.16146

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To improve the credibility of ROR by removing false positives caused by a lack of absolute counts, we presented a unique method to verify the validity of ROR values. Those adverse events The vast majority of reported cases of thrombosis are related to vaccination with ChAdOx1nCoV-19 (Bayas et al, 2021;Schultz et al, 2021) or Ad26.COV2.S (Iavorska et al, 2021;See et al, 2021). There was also a case report of cerebral venous sinus thrombosis after the Pfizer-BioNTech vaccination (Cheng, 2021).…”

Section: Discussionmentioning

confidence: 99%

“…The vast majority of reported cases of thrombosis are related to vaccination with ChAdOx1nCoV-19 ( Bayas et al, 2021 ; Schultz et al, 2021 ) or Ad26.COV2.S ( Iavorska et al, 2021 ; See et al, 2021 ). There was also a case report of cerebral venous sinus thrombosis after the Pfizer-BioNTech vaccination ( Cheng, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

“…The serious adverse events following immunization (AEFI) reported concerning the COVID-19 vaccines also include thrombosis ( Marcucci et al, 2021 ), thrombocytopenia ( Welsh et al, 2021 ), and several cases of unusual thrombotic events in combination with thrombocytopenia ( Gunther et al, 2021 ; Iavorska et al, 2021 ). The vast majority of reported immune thrombotic thrombocytopenia (VITT) cases have occurred following adenoviral vector-based vaccination with ChAdOx1nCoV-19 (Oxford/AstraZeneca) ( Bayas et al, 2021 ; Schultz et al, 2021 ) or Ad26.COV2.S ( Bayas et al, 2021 ; Iavorska et al, 2021 ; Schultz et al, 2021 ; See et al, 2021 ). It is unclear whether thrombosis is related to the Pfizer-BioNTech and mRNA-1273 vaccines or whether BNT162b2 and Ad26.COV2.S recipients have a similar frequency of blood clots and bleeding.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS

Yan¹,

Zhao²,

Li³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background and purpose: Serious adverse events following immunization (AEFI) associated with the COVID-19 vaccines, including BNT162b2 (Pfizer-BioNTech), Ad26.COV2.S (Janssen), and mRNA-1273 (Moderna), have not yet been fully investigated. This study was designed to evaluate the serious AEFI associated with these three vaccines.Methods: A disproportionality study was performed to analyze data acquired from the Vaccine Adverse Event-Reporting System (VAERS) between 1 January 2010 and 30 April 2021. The reporting odds ratio (ROR) method was used to identify the association between the COVID-19 vaccines BNT162b2, Ad26.COV2.S, and mRNA-1273 and each adverse event reported. Moreover, the ratio of the ROR value to the 95% CI span was applied to improve the credibility of the ROR. The median values of time from vaccination to onset (TTO) for the three vaccines were analyzed.Results: Compared with BNT162b2 and mRNA-1273, Ad26.COV2.S vaccination was associated with a lower death frequency (p < 0.05). Ad26.COV2.S vaccination was associated with a lower birth defect and emergency room visit frequency than BNT162b2 (p < 0.05). There were 6,605, 830, and 2,292 vaccine recipients who suffered from COVID-19-related symptoms after vaccination with BNT162b2, Ad26.COV2.S, and mRNA-1273, respectively, including people who were infected by COVID-19, demonstrated a positive SARS-CoV-2 test, and were asymptomatic. Serious AEFI, including thromboembolism, hemorrhage, thrombocytopenia, cardiac arrhythmia, hypertension, and hepatotoxicity, were associated with all three vaccines. Cardiac failure and acute renal impairment events were associated with BNT162b2 and mRNA-1273, while seizure events were associated with BNT162b2 and Ad26.COV2.S. The median values of TTO associated with the three vaccinations were similar.Conclusion: These findings may be useful for health workers and the general public prior to inoculation, especially for patients with underlying diseases; however, the risk/benefit profile of these vaccines remains unchanged. The exact mechanism of SARS-CoV-2 vaccine-induced AEFI remains unknown, and further studies are required to explore these phenomena.

show abstract